Depo-Provera Brain Tumor Investigation

If you were diagnosed with a Meningioma Tumor after using Depo-Provera birth control, you may have legal options.

Please Click HERE to Contact Us for a Free Consultation

Berger Montague PC is investigating claims that the injectable birth control drug Depo-Provera may increase the risk of brain tumors known as meningiomas.

What is Depo-Provera?

Depo-Provera, and its lower dose version Depo-SubQ Provera 104, are birth control drugs with the active ingredient medroxyprogesterone acetate. They do not contain estrogen and are a progestin-based hormonal contraceptives that are administered through an injection every three months. Approximately 74 million women use the birth control shot worldwide with 2 million located in the United States.

In addition to its use as a contraceptive, Depo-Provera is also prescribed to manage certain medical conditions, such as endometriosis and irregular periods.

Study connects drug with tumors

A recent study in the March 2024 issue of the British Medical Journal by researchers at France’s National Agency for Medicines and Health Products Safety identified a link between Depo-Provera use and meningiomas. Researchers found that prolonged administration of progestogen-based drugs resulted in a five and a half times risk of developing meningiomas.

• Women using Depo-Provera for birth control are 5 times more likely to develop meningiomas, according to the BMJ.

What are meningiomas?

Meningiomas are generally benign tumors that grow slowly from the membranes that surround the brain and spinal cord. The tumors usually do not cause symptoms, but they can affect the nearby brain tissue, nerves, or vessels, leading to significant disabilities and potentially necessitating their removal.

Symptoms of a meningioma may include:

• Blurred vision
• Confusion
• Seizures
• Trouble speaking
• Double vision
• Arm or leg weakness
• Loss of smell
• Hearing loss
• Memory loss
• Vision loss

Undisclosed risk

Despite being aware of the risk of developing a meningioma with the use of Depo-Provera, Pfizer, the manufacturer of Depo-Provera, did not warn of this risk. Pfizer said in a statement: “We are aware of this potential risk associated with long-term use of progestogens and, in collaboration with regulatory agencies, are in the process of updating product labels and patient information leaflets with appropriate wording.”

Individuals may qualify for a lawsuit related to Depo-Provera if they were diagnosed with a brain tumor after using the drug for more than a year.

About Berger Montague

Berger Montague is one of the nation’s preeminent law firms focusing on complex civil litigation, class actions and mass torts in federal and state courts throughout the United States. The firm is active in the fields of antitrust, commercial litigation, consumer protection, defective products, environmental law, employment law, securities and whistleblower cases, among other practice areas. For more than 50 years Berger Montague has played leading roles in precedent-setting cases and has recovered over $60 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago, Minneapolis, San Diego, San Francisco, Toronto, Washington, D.C., and Wilmington, DE.